Phase II Trial of Lenalidomide - Rituximab ± Dexamethasone in Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

被引：0
作者：
Ahmadi, Tahamtan
Chong, Elise A. [1 ]
Gordon, Amanda [1 ]
Aqui, Nicole A. [2 ]
Xu, YinYan [2 ]
Svoboda, Jakub [1 ]
Nasta, Sunita D. [1 ]
Schuster, Stephen J. [1 ]
机构：
[1] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 123
页数：2
相关论文
共 50 条
  • [21] Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    Zhang, Liang
    Fayad, Luis
    Hagemeister, Fredrick
    Neelapu, Sattva
    Samaniego, Felipe
    Pro, Barbara
    Younes, Anas
    Miller, Scott
    Knight, Robert D.
    Zeldis, Jerome B.
    Yi, Qing
    Romaguera, Jorge
    BLOOD, 2008, 112 (11) : 1051 - 1051
  • [22] Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma
    Barr, Paul M.
    Fu, Pingfu
    Lazarus, Hillard M.
    Horvath, Nancy
    Gerson, Stanton L.
    Koc, Omer N.
    Bahlis, Nizar J.
    Snell, Michael R.
    Dowlati, Afshin
    Cooper, Brenda W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (01) : 89 - 96
  • [23] BENDAMUSTINE AND RITUXIMAB COMBINATION THERAPY WITH SUBSEQUENT RITUXIMAB SUPPORTING THERAPY IN RUSSIAN SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMAS
    Poddubnaya, I.
    Babicheva, L.
    Melnichenko, V.
    Volodicheva, E.
    Kuznetsova, E.
    Tyurina, N.
    Kaplanov, K.
    Kaporskaya, T.
    Olkin, D.
    Domnikova, N.
    Bakhtina, V.
    Mladov, V.
    Kanhai, K.
    HAEMATOLOGICA, 2017, 102 : 748 - 749
  • [24] LENALIDOMIDE MONOTHERAPY OR IN COMBINATION WITH RITUXIMAB OR STEROIDS IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAS: RESULTS OF A RETROSPECTIVE ANALYSIS
    Castellino, A.
    Chiappella, A.
    Ghione, P.
    Matteucci, P.
    Ceccarelli, M.
    Benevolo, G.
    Botto, B.
    Caracciolo, D.
    Cavallo, F.
    Ciochetto, C.
    Ferrero, S.
    Nicolosi, M.
    Orsucci, L.
    Pregno, P.
    Riccomagno, P.
    Devizzi, L.
    Vitolo, U.
    HAEMATOLOGICA, 2015, 100 : 93 - 93
  • [25] Changes in regulatory T-cells in responding and non-responding patients with indolent B-cell or mantle cell lymphomas during treatment with lenalidomide, dexamethasone, and rituximab.
    Aqui, N.
    Leinbach, L.
    Chong, E. A.
    Ahmadi, T.
    Svoboda, J.
    Gordon, A.
    Downs, L. H.
    Nesta, S.
    Schuster, S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas
    Cheson, Bruce D.
    Crawford, Jeanette
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 528 - 533
  • [27] Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
    Wang, Michael
    Fayad, Luis
    Wagner-Bartak, Nicolaus
    Zhang, Liang
    Hagemeister, Fredrick
    Neelapu, Sattva S.
    Samaniego, Felipe
    McLaughlin, Peter
    Fanale, Michelle
    Younes, Anas
    Cabanillas, Fernando
    Fowler, Nathan
    Newberry, Kate J.
    Sun, Luhong
    Young, Ken H.
    Champlin, Richard
    Kwak, Larry
    Feng, Lei
    Badillo, Maria
    Bejarano, Maria
    Hartig, Kimberly
    Chen, Wendy
    Chen, Yiming
    Byrne, Catriona
    Bell, Neda
    Zeldis, Jerome
    Romaguera, Jorge
    LANCET ONCOLOGY, 2012, 13 (07) : 716 - 723
  • [28] Lenalidomide in combination with rituximab is effective with manageable toxicity in a phase I/II study in relapsed/refractory mantle cell lymphoma
    Wang, M.
    Fayad, L.
    Hagemeister, F.
    Neelapu, S.
    Samuels, B.
    Samanigo, F.
    Pro, B.
    Yi, Q.
    Bell, N.
    Byrne, C.
    Weaver, P.
    Hartig, K.
    Knight, R.
    Zeldis, J.
    Kwak, L.
    Romaguera, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 174 - 174
  • [29] High Response Rate To Combination Lenalidomide-Rituximab In FcγRIIIa-F Carriers With Indolent Or Mantle Cell Lymphomas Previously Refractory To Rituximab
    Chong, Elise A.
    Ahmadi, Tahamtan
    Aqui, Nicole A.
    Nasta, Sunita D.
    Svoboda, Jakub
    Walsh, Kristy M.
    Gordon, Amanda
    Schuster, Stephen J.
    BLOOD, 2013, 122 (21)
  • [30] Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma
    Yun Hou
    Hua-qing Wang
    Yi Ba
    Medical Oncology, 2012, 29 : 2409 - 2416
12345